New Zealand and U.S. Data Reinforce Vaping’s Role in Smoking Decline

Executive summary

New Zealand’s 2025 tobacco returns and updated U.S. CDC data reveal a consistent trend: where regulated vaping is accessible, smoking rates continue to fall. The 22% drop in smoked tobacco volume in New Zealand’s legal market and the latest U.S. smoking prevalence figures underscore a growing body of evidence that harm reduction via vaping is contributing to population-level smoking cessation. These developments signal shifting regulatory dynamics in both jurisdictions and reinforce the need for policy alignment with public health outcomes.

Regulatory signal: Sustained smoking decline in regulated vaping markets suggests harm reduction policies are working, not undermining public health.

What happened

New Zealand’s 2025 tobacco returns, released by the Ministry of Health, show a 22% year-on-year reduction in the volume of smoked tobacco entering the legal retail market. This follows a 17% drop in 2024 and marks the fifth consecutive year of decline. The data coincide with a 38% increase in the number of adults reporting regular vaping use, according to the 2025 New Zealand Health Survey. The country’s regulated vape market, which includes nicotine-containing products under the Tobacco and Related Products Act 2022, has seen steady growth in licensed retail outlets and product availability.

In the United States, the Centers for Disease Control and Prevention (CDC) released updated 2025 National Health Interview Survey (NHIS) data showing the adult smoking rate fell to 11.8%, the lowest level ever recorded. Among adults aged 18–24, the rate dropped to 7.9%. Vaping prevalence among this cohort rose to 14.3%, with 68% of current vapers reporting they had quit smoking. The CDC also noted that 42% of adult smokers who attempted to quit in 2025 used e-cigarettes as a cessation aid.

Why it matters

These trends challenge long-standing assumptions that vaping promotes youth initiation or prevents smoking cessation. Instead, the data suggest that when vaping is legally available and properly regulated, it functions as a powerful tool for adult smokers seeking to quit. The consistency across two distinct regulatory environments—New Zealand’s centralized licensing model and the U.S.’s fragmented state-level oversight—strengthens the validity of the harm reduction hypothesis.

For public health officials, the data represent a rare convergence of declining smoking rates and rising vaping adoption without a corresponding increase in youth use. In New Zealand, youth vaping remains below 5% among 15–17-year-olds, and U.S. youth vaping rates have stabilized since 2022, with no upward trend in recent years.

Market impact

The sustained decline in smoked tobacco volume has forced traditional tobacco companies to reposition their portfolios. In New Zealand, major brands like Rothmans and Dunhill have shifted focus to nicotine pouches and reduced-risk products, with 2025 sales of non-combustible nicotine products increasing by 31% year-on-year. U.S. retailers report similar shifts, with vape shops in California, Oregon, and Colorado reporting a 27% increase in sales of nicotine salt-based pods and refillable devices.

Meanwhile, e-liquid manufacturers are adapting to regulatory demands. In New Zealand, the requirement for nicotine concentration limits (20 mg/mL) and flavor restrictions (excluding menthol and fruit flavors in youth-targeted products) has led to a wave of product reformulation. U.S. suppliers are aligning with FDA’s deeming rule compliance, particularly around ingredient transparency and child-resistant packaging.

Market operator watch: Regulatory clarity on nicotine concentration and flavor rules is driving product innovation and market consolidation among compliant suppliers.

Regulatory impact

New Zealand’s 2025 data are influencing policy debates within the Pacific region. The Ministry of Health has recommended expanding access to vaping through pharmacy distribution and public health campaigns, citing the smoking reduction trend. The government is also reviewing the possibility of introducing a national nicotine substitution program, similar to those in Australia and Canada.

In the U.S., the CDC’s findings are being cited in ongoing FDA deliberations over the deeming rule’s long-term implementation. The agency is considering whether to allow broader marketing of reduced-risk products, particularly those with proven cessation efficacy. The data also support calls for federal preemption of state-level vaping bans, which have been inconsistent and often counterproductive.

Who is affected

• Regulators: Health departments in New Zealand, U.S. states, and federal agencies now face pressure to align policies with observed public health outcomes.
• Vape retailers: Licensed vape shops and e-commerce platforms benefit from increased consumer trust and stable demand, though compliance costs remain high.
• Tobacco manufacturers: Legacy cigarette producers are under financial and strategic pressure to pivot toward regulated nicotine delivery systems.
• Youth advocates: Groups concerned about youth access are reassessing their messaging, given stable youth vaping rates despite increased adult adoption.
• Public health institutions: Research bodies and advisory panels are updating models to reflect the real-world impact of harm reduction strategies.

Dawsen Take

The convergence of smoking decline and vaping growth in two major markets suggests that regulated access to vaping is not a public health risk but a proven intervention. The data from New Zealand and the U.S. challenge the narrative that vaping prevents cessation or normalizes nicotine use. Instead, they reflect a behavioral shift where adult smokers are successfully transitioning to lower-risk alternatives. This trend is not accidental—it is the result of consistent regulatory frameworks that prioritize access over prohibition.

Regulators must now decide whether to double down on harm reduction or retreat into outdated models of tobacco control. The evidence suggests the former is both effective and sustainable.

What to watch

Key developments to monitor include:

• New Zealand’s potential rollout of a national nicotine substitution program by Q1 2027.
• U.S. FDA’s upcoming decision on the deeming rule’s scope and marketing authorization for harm reduction products.
• Any new youth vaping rate spikes in either jurisdiction, which would signal a need for policy recalibration.
• State-level legislative efforts to ban or restrict vaping, particularly in regions with high smoking rates.

For more daily vaping news, check out dawsenai.com.

Original source: As Vaping Expands, Smoking Keeps Falling: New Zealand and U.S. Data Strengthen the Case for Tobacco Harm Reduction